APP-Based Transgenic Models: The APP23 Model


Guénette SY, Tanzi RE (1999) Progress toward valid transgenic mouse models for Alzheimer’s disease. Neurobiol Aging 20:201–211.PubMedCrossRef


Sturchler-Pierrat C, Abramowski D, Duke M et al (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94:13287–13292.CrossRef


Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766.PubMed


Bornemann KD, Staufenbiel M (2000) Transgenic mouse models of Alzheimer’s disease. Ann N Y Acad Sci 908:260–266.PubMedCrossRef


Sturchler-Pierrat C, Staufenbiel M (2000) Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 920:134–139.PubMedCrossRef


Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109:813–8136.PubMedCrossRef


Calhoun ME, Burgermeister P, Phinney AL et al (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 96:14088–14093.PubMedCrossRef


Winkler DT, Bondolfi L, Herzig MC et al (2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21:1619–1627.PubMed


Kuo YM, Beach TG, Sue LI et al (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7:609–618.PubMed


Van Dam D, D’Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17:388–396.PubMedCrossRef


Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154:1673–1684.PubMedCrossRef


Bornemann KD, Wiederhold KH, Pauli C et al (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158:63–73.PubMedCrossRef


Stalder M, Deller T, Staufenbiel M (2001) Jucker M. 3D-reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging 22:427–434.PubMedCrossRef


Calhoun ME, Wiederhold KH, Abramowski D et al (1998) Neuron loss in APP transgenic mice. Nature 395:755–756.PubMedCrossRef


Boncristiano S, Calhoun ME, Howard V et al (2005) Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging 26:607–613.PubMedCrossRef


Bondolfi L, Calhoun M, Ermini F et al (2002) Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 22:515–522.PubMed


Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122–126.PubMedCrossRef


Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190.PubMedCrossRef


Boncristiano S, Calhoun ME, Kelly PH et al (2002) Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 22:3234–3243.PubMed


Van Dam D, Marescau B, Engelborghs S et al (2005) Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int 46:409–422.PubMedCrossRef
< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 18, 2016 | Posted by in EXOTIC, WILD, ZOO | Comments Off on APP-Based Transgenic Models: The APP23 Model

Full access? Get Clinical Tree

Get Clinical Tree app for offline access